March 23, 2018 / 6:10 AM / in 3 months

BRIEF-Exelixis' Partner Ipsen Announces Positive CHMP Opinion For Cabometyx

March 23 (Reuters) - Exelixis Inc:

* EXELIXIS’ PARTNER IPSEN ANNOUNCES POSITIVE CHMP OPINION FOR CABOMETYX FOR PREVIOUSLY UNTREATED INTERMEDIATE- OR POOR-RISK ADVANCED RENAL CELL CARCINOMA​

* EXELIXIS IS ELIGIBLE TO RECEIVE A MILESTONE PAYMENT OF $50 MILLION FOR APPROVAL OF FIRST-LINE TREATMENT OF ADVANCED RCC​

* ‍POSITIVE CHMP OPINION WILL NOW BE REVIEWED BY EUROPEAN COMMISSION​ Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below